Pharming Group: FDA Acceptance Of Supplemental NDA, Priority Review For Leniolisib In Children With APDS

Pharming Group NV PHARM:

• PHARMING GROUP ANNOUNCES U.S. FDA ACCEPTANCE AND PRIORITY REVIEW OF SUPPLEMENTAL NEW DRUG APPLICATION FOR LENIOLISIB IN CHILDREN WITH APDS AGED 4 TO 11 YEARS

• PDUFA TARGET ACTION DATE SET FOR JANUARY 31, 2026

• DECISION BASED ON POSITIVE PHASE III STUDY DATA